Global CBC + CRP + SAA Combined Analyzer Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032

According to our (Global Info Research) latest study, the global CBC + CRP + SAA Combined Analyzer market size was valued at US$ 98 million in 2025 and is forecast to a readjusted size of US$ 171 million by 2032 with a CAGR of 8.3% during review period.
CBC + CRP + SAA combined analyzers are in vitro diagnostic instruments that integrate hematology analysis and specific-protein immunoassay on a single platform, allowing one venous or capillary whole-blood sample to generate complete blood count, C-reactive protein, and serum amyloid A results. Blood-cell counting and differentiation are generally performed using electrical impedance, laser light scattering, or flow-based technologies, while CRP and SAA are measured by latex-enhanced immunoturbidimetry, immunonephelometry, or fluorescence immunoassay. The combined results support infection and inflammation screening, disease-course monitoring, and rapid clinical triage. Major product configurations include cartridge-based point-of-care systems, manually loaded benchtop analyzers, and autosampler-equipped benchtop instruments. Key upstream components and materials include semiconductor lasers, photodetectors, flow cells, counting chambers, precision pumps and valves, sampling probes, reaction cuvettes, temperature-control modules, control boards, touchscreens, antibodies, latex particles, lysing reagents, diluents, calibrators, and controls. Major downstream customers include hospital laboratories, emergency departments, fever clinics, pediatric and maternal-care institutions, primary healthcare facilities, outpatient clinics, independent clinical laboratories, and health-screening centers. Based on a conservative assessment, global effective production capacity in 2025 was approximately 10,900 units, with sales of around 7,463 units, a weighted average ex-factory price of approximately USD 12,760 per unit, and an equipment gross margin of approximately 36%-48%.
The global market for CBC + CRP + SAA combined analyzers remains centered on China in terms of both demand and supply. Leading manufacturers have established product portfolios covering three-part and five-part differential systems, manual-loading and autosampler-equipped instruments, and cartridge-based point-of-care platforms. Compared with configurations that require separate hematology and specific-protein analyzers, combined systems can use a single blood sample to provide blood-cell counts, differential results, and inflammatory markers, making them well suited to emergency departments, pediatric facilities, fever clinics, and primary-care settings that require small sample volumes, rapid turnaround, and simplified workflows. Competition is shifting from basic three-test capability toward differentiation accuracy, CRP and SAA measurement range, low-concentration stability, capillary-blood handling, instrument reliability, and total reagent cost.
Hospitals remain the largest downstream customer group, with relatively strong demand from emergency, pediatric, maternal-care, and infection-related departments. As laboratory workflows become more integrated, single-tube combined testing can reduce repeated blood collection, sample transportation, and waiting time between different instruments, supporting faster patient triage and clinical decision-making. Primary-care customers place greater emphasis on compact size, ease of maintenance, operator training, reagent-storage requirements, and cost per test, encouraging the development of cartridge-based, closed-reagent, and low-maintenance systems. Future demand is expected to come mainly from hospital equipment replacement, expansion of primary diagnostic capabilities, and the entry of Chinese manufacturers into Southeast Asia, the Middle East, Latin America, and other emerging markets.
From a technology perspective, products are evolving from fixed CBC, CRP, and SAA combinations into broader integrated hematology platforms. Some medium- and high-end analyzers already incorporate reticulocytes, nucleated red blood cells, immature granulocytes, erythrocyte sedimentation rate, and additional specific-protein parameters, while automatic loading, capillary-blood mixing, abnormal-sample rerun, and automated result validation improve laboratory efficiency. Cartridge-based systems reduce contamination and maintenance risks through preloaded reagents, disposable reaction components, and simplified fluidics. As AI-assisted morphology, remote quality control, reagent inventory management, and LIS/HIS connectivity become more widely adopted, competition will increasingly extend beyond instrument performance to workflow integration, data management, and service capability.
The principal limitation is that clinical practice, reimbursement, and guideline support for SAA testing vary significantly between countries, and acceptance of a fixed CBC + CRP + SAA panel remains relatively limited in many developed markets. Combined results can support infection and inflammation assessment, but they do not replace pathogen testing, imaging, or comprehensive clinical diagnosis, and their value still depends on appropriate interpretation and quality control. Instruments also commonly rely on closed reagent systems, meaning customers evaluate not only the purchase price but also long-term reagent costs, supply stability, regulatory registration, and service coverage. The market will therefore increasingly favor manufacturers with proprietary assay technologies, reliable reagent systems, strong clinical validation, and international registration capabilities, while companies with highly similar products and weak distribution or service networks will face greater competitive pressure.
This report is a detailed and comprehensive analysis for global CBC + CRP + SAA Combined Analyzer market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global CBC + CRP + SAA Combined Analyzer market size and forecasts, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global CBC + CRP + SAA Combined Analyzer market size and forecasts by region and country, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global CBC + CRP + SAA Combined Analyzer market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global CBC + CRP + SAA Combined Analyzer market shares of main players, shipments in revenue ($ Million), sales quantity (Units), and ASP (US$/Unit), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for CBC + CRP + SAA Combined Analyzer
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global CBC + CRP + SAA Combined Analyzer market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Mindray, Dymind Biotechnology, EDAN Instruments, Maccura Biotechnology, Genrui Biotech, Goldsite Diagnostics, Shenzhen Comen Medical Instruments, Medconn Diagnostics, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
CBC + CRP + SAA Combined Analyzer market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
3-Part Differential
5-Part Differential
Market segment by Product Configuration
Cartridge-based POCT
Manual-loading Benchtop
Autosampler-equipped Benchtop
Market segment by Rated CBC Throughput
≤30 Tests/Hour
31-60 Tests/Hour
>60 Tests/Hour
Market segment by Application
Hospital
Clinic
Others
Major players covered
Mindray
Dymind Biotechnology
EDAN Instruments
Maccura Biotechnology
Genrui Biotech
Goldsite Diagnostics
Shenzhen Comen Medical Instruments
Medconn Diagnostics
Market segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe CBC + CRP + SAA Combined Analyzer product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of CBC + CRP + SAA Combined Analyzer, with price, sales quantity, revenue, and global market share of CBC + CRP + SAA Combined Analyzer from 2021 to 2026.
Chapter 3, the CBC + CRP + SAA Combined Analyzer competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the CBC + CRP + SAA Combined Analyzer breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and CBC + CRP + SAA Combined Analyzer market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of CBC + CRP + SAA Combined Analyzer.
Chapter 14 and 15, to describe CBC + CRP + SAA Combined Analyzer sales channel, distributors, customers, research findings and conclusion.